Whereas low-count MBL almost never progresses to CLL, higher-depend MBL progresses to CLL demanding therapy in a fee of 1% to two% annually. High-rely MBL is distinguished from Rai 0 CLL according to whether or not the B-cell rely is above or under five × 109/L. Despite the fact that individuals with equally high-count MBL and CLL Rai phase 0 are